MedKoo product information:

Ortataxel

Ortataxel is a drug used in chemotherapy. As of June 2009[update], Spectrum Pharmaceuticals has the drug is in a Phase 2 clinical trial.

The novel taxane, IDN5109, is characterized by its high tolerability, antitumor efficacy, ability to overcome multidrug resistance, and oral bioavailabilty. In in vitro experiments, IDN5109 showed antiproliferative effects against HNSCC cell lines. After treatment with IDN5109, Bcl-2 and Bcl-XL were down-regulated, Bax was up-regulated, and caspase-3 was activated. After treatment with IDN5109, concentrations of both VEGF and IL-8 in the culture supernatant of HNSCC cells decreased. In in vivo experiments, the oral administration of IDN5109 showed antitumor effects against HNSCC tumor xenografts. Immunohistochemistry showed that IDN5109 inhibited tumor angiogenesis and induced apoptosis in HNSCC cells, producing a decreased blood vessel density and increased apoptosis index. On the basis of these results, IDN5109 is useful as a chemotherapeutic agent against HNSCC. See: Oncol Rep. 2006 Feb;15(2):329-34. http://www.ncbi.nlm.nih.gov/pubmed/16391850 .

Current developer:    Indena (Originator), State University of New York, Albany (Originator), Bayer (Licensee); Spectrum Pharmaceuticals, Inc  (Licensee).

 1: Xiang F, Yu J, Yin R, Ma Y, Yu L. Structure-activity relationship of taxol inferring from docking taxol analogues to microtubule binding site. Z Naturforsch C. 2009 Jul-Aug;64(7-8):551-6. PubMed PMID: 19791508.

2: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PubMed PMID: 19088949.

3: Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Med Chem. 2005 Mar;1(2):125-39. Review. PubMed PMID: 16787308.

4: Sano D, Matsuda H, Ishiguro Y, Nishimura G, Kawakami M, Tsukuda M. Antitumor effects of IDN5109 on head and neck squamous cell carcinoma. Oncol Rep. 2006 Feb;15(2):329-34. PubMed PMID: 16391850.

5: Song L, Prey JD, Xue J, Kanter P, Manzotti C, Bombardelli E, Morazzoni P, Pendyala L. Pharmacokinetic measurements of IDN 5390 using electrospray ionization tandem mass spectrometry: structure characterization and quantification in dog plasma. Rapid Commun Mass Spectrom. 2005;19(24):3617-25. PubMed PMID: 16299696.

6: Barboni L, Ballini R, Giarlo G, Appendino G, Fontana G, Bombardelli E. Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5182-6. Epub 2005 Sep 23. PubMed PMID: 16183281.

7: Lavelle F. American Association for Cancer Research 1999: 10-14 April, Philadelphia, Pennsylvania. Expert Opin Investig Drugs. 1999 Jun;8(6):903-9. PubMed PMID: 15992139.

8: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Oct;26(8):639-63. PubMed PMID: 15605126.

9: Eckstein JW. Drug evaluation: Bay-59-8862. IDrugs. 2004 Jun;7(6):575-81. Review. PubMed PMID: 15197663.

10: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PubMed PMID: 15148527.

11: Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol. 2004 May;53(5):363-9. Epub 2004 Jan 27. PubMed PMID: 15060738.

12: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. Review. PubMed PMID: 14988742.

13: Baldelli E, Battaglia A, Bombardelli E, Carenzi G, Fontana G, Gambini A, Gelmi ML, Guerrini A, Pocar D. Diastereoselective 14beta-hydroxylation of baccatin III derivatives. J Org Chem. 2003 Dec 12;68(25):9773-9. PubMed PMID: 14656106.

14: Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. 2003 Nov;2(11):1195-205. Erratum in: Mol Cancer Ther. 2004 Jan;3(1):101. Brooks, Tracy [corrected to Brooks, Tracy A]. PubMed PMID: 14617793.

15: Maison W, Frangioni JV. Improved chemical strategies for the targeted therapy of cancer. Angew Chem Int Ed Engl. 2003 Oct 13;42(39):4726-8. PubMed PMID: 14562338.

16: Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G, Bombardelli E, Zunino F. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res. 2002 Aug;8(8):2647-54. PubMed PMID: 12171897.

17: Ojima I, Geney R, Ungureanu IM, Li D. Medicinal chemistry and chemical biology of new generation taxane antitumor agents. IUBMB Life. 2002 Apr-May;53(4-5):269-74. Review. PubMed PMID: 12121008.

18: Lavelle F. [New taxanes and epothilone derivatives in clinical trials]. Bull Cancer. 2002 Apr;89(4):343-50. Review. French. PubMed PMID: 12016034.

19: Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer. 2002 Mar 20;98(3):463-9. PubMed PMID: 11920601.

20: Jordan MA, Ojima I, Rosas F, Distefano M, Wilson L, Scambia G, Ferlini C. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis. Chem Biol. 2002 Jan;9(1):93-101. PubMed PMID: 11841942.

21: Laccabue D, Tortoreto M, Veneroni S, Perego P, Scanziani E, Zucchetti M, Zaffaroni M, D'Incalci M, Bombardelli E, Zunino F, Pratesi G. A novel taxane active against an orthotopically growing human glioma xenograft. Cancer. 2001 Dec 15;92(12):3085-92. PubMed PMID: 11753988.

22: Sottani C, Colombo T, Zucchetti M, Fruscio R, D'Incalci M, Minoia C. High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. Rapid Commun Mass Spectrom. 2001;15(19):1807-16. PubMed PMID: 11565098.

23: Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J Natl Cancer Inst. 2001 Aug 15;93(16):1234-45. PubMed PMID: 11504769.

24: Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des. 2001 Sep;7(13):1251-7. Review. PubMed PMID: 11472265.

25: Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer. 2001 Jun 1;92(5):738-47. PubMed PMID: 11340581.

26: von Angerer E. Tubulin as a target for anticancer drugs. Curr Opin Drug Discov Devel. 2000 Sep;3(5):575-84. PubMed PMID: 19649885.

27: Ferlini C, Distefano M, Pierelli L, Bonanno G, Riva A, Bombardelli E, Ojima I, Mancuso S, Scambia G. Cytotoxic effects toward human hematopoietic progenitor cells and tumor cell lines of paclitaxel, docetaxel, and newly developed analogues IDN5109, IDN5111, and IDN5127. Oncol Res. 1999;11(10):471-8. PubMed PMID: 10850888.

28: Polizzi D, Pratesi G, Monestiroli S, Tortoreto M, Zunino F, Bombardelli E, Riva A, Morazzoni P, Colombo T, D'Incalci M, Zucchetti M. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res. 2000 May;6(5):2070-4. PubMed PMID: 10815934.

29: Nicoletti MI, Colombo T, Rossi C, Monardo C, Stura S, Zucchetti M, Riva A, Morazzoni P, Donati MB, Bombardelli E, D'Incalci M, Giavazzi R. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res. 2000 Feb 15;60(4):842-6. PubMed PMID: 10706091.

30: Colombo T, Frapolli R, Bombardelli E, Morazzoni P, Riva A, D'Incalci M, Zucchetti M. High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):135-41. PubMed PMID: 10676993.

31: Distefano M, Scambia G, Ferlini C, Gaggini C, De Vincenzo R, Riva A, Bombardelli E, Ojima I, Fattorossi A, Panici PB, Mancuso S. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer. 1997 Sep 4;72(5):844-50. Erratum in: Int J Cancer 1998 Mar 30;76(1):164. PubMed PMID: 9311603.